HeartSciences Inc. Q1 2027: Revenue $2.1K, Net loss $(3.17M), EPS $(0.86) — 10-Q Summary
HeartSciences Inc. reported Q1 2027 fiscal results with revenue of $2.1K, a net loss of $3.17M, and EPS of $(0.86). Revenue was flat year-over-year, while the net loss widened from $(2.06M). The company launched MyoVista Insights™ upgrades and an AI marketplace, signed commercial agreements, and submitted a 510(k) for the wavECG device.
How this was made
The 30-second read
Why it matters
The earnings release provides the first public numbers for the quarter, offering new data for traders.
Market read
Micro‑cap earnings with a loss expansion; limited immediate market impact but relevant for niche AI‑health investors.
What to watch
Recent FDA 510(k) submission and European patent grant could unlock future revenue streams.
Background
HeartSciences filed a 10‑Q for the quarter ended July 31, 2026, reporting flat revenue and widened loss.
Ticker impact
Q1 2027 earnings released with revenue $2.1K and net loss $3.17M, first public disclosure of the quarter.
potential short-term downside pressure
Micro‑cap earnings with widening loss typically trigger sell pressure absent positive guidance.
Market effects
Limited; reflects ongoing challenges in digital health AI‑ECG niche.
Minimal impact on broader US market.
Low; company is a micro‑cap with niche exposure.
Counterpoint
If the AI‑ECG marketplace gains traction, the loss may be temporary and could present a buying opportunity.
Key entities
- companyHeartSciences Inc.
Digital health company developing AI‑ECG platform.
